Sandra Guardiola-Vilarroig

Sandra Guardiola-Vilarroig

Auto-generated profile, based on publicly available information

Sandra Guardiola-Vilarroig

Unidad Mixta de Investigación en Enfermedades Raras; Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana-Universitat de València (FISABIO-UVEG). Valencia. España

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Atencion Primaria
Verified
Journal Article
Open access
ABAna Boned-Ombuena
Ana Boned-Ombuena
JPJordi Perez Panades
Jordi Perez Panades
ALAurora López-Maside
Aurora López-Maside
MMMaite Miralles-Espí
Maite Miralles-Espí
SVSandra Guardiola Vilarroig
Sandra Guardiola Vilarroig
Oscar ZurriagaOscar Zurriaga
Oscar Zurriaga
To estimate the prevalence of patients with oral anticoagulant therapy (OAT) in the Region of Valencia and to evaluate the quality of management of OAT with vitaminK antagonists (VKA) carried out in primary healthcare. Observational cross-sectional study conducted through the Health Sentinel Network of the Region of Valencia, which includes a survey and the retrospective analysis of OAT monitoring. Primary healthcare, Region of Valencia, Spain. All patients aged 18years or older on OAT who consulted during the year 2014. The population covered by the 59 doctors of the Health Sentinel Network constitutes 2.2% of the adult population of the Region of Valencia, and it is representative of it. Demographic, socioeconomic and health data as well as information concerning OAT. Quality of OAT management with VKA was assessed by means of the percentage of time in therapeutic range (TTR), computed using the Rosendaal method. A total of 1,144 patients were recorded (mean age 74.5±11 years; 49.7% women). Prevalence of OAT in the Region of Valencia is 1.3 cases per 100 population. The characteristic profile of these patients is an old person, with several comorbidities and a low level of education, who lives accompanied. Atrial fibrillation is the most common indication. 82.8% of patients on OAT with VKA were monitored in primary healthcare. The average TTR was 65.0%, and 53.9% of patients had a TTR ≥65%. Among inadequately controlled patients, 74.4% were perceived as well-controlled by their primary care doctor. Prevalence of OAT is high, and it is expected to increase. The degree of control achieved meets the generally accepted quality standard (mean TTR ≥65%), and it is comparable to that observed in other national and international studies. However, there is wide scope for improvement. It is crucial to optimize the management of this therapy in the most effective and cost-effective way. Among other measures, access of physicians to their patients' clinical information should be improved.

28 November 2017
Verified
Journal Article
Open access
SGSilvia Gimeno-Martos
Silvia Gimeno-Martos
CPCarlos Pérez-Riera
Carlos Pérez-Riera
SGSandra Guardiola-Vilarroig
Sandra Guardiola-Vilarroig
CCClara Cavero-Carbonell
Clara Cavero-Carbonell
Osteogenesis imperfecta (OI) is a rare connective tissue and bone disease that results in a bone fragility of varying severity. The objective was to determine and describe the OI in the Valencia Region (VR) during the period 2004 to 2014. From the Rare Diseases Information System of the VR (SIER-CV) patients from 2004 to 2014 with the codes of the International Classification of Diseases for the OI were identified: 756.51 from the 9th Revision-Clinical Modification and Q78.0 from the 10th Revision. The information was validated by reviewing clinical documentation (mainly electronic health records) and a descriptive analysis of the confirmed cases (diagnosis of OI in the clinical documentation) was performed. 162 patients were identified with a code for OI. 145 of the 161 patients with available clinical documentation were confirmed as cases. The prevalence was 0.29 per 10.000 inhabitants. 93.1% were Spanish, 54.5% were women and they were treated in 25 different hospitals in the VR. The type of OI was known in the 26.4% of the cases and type I was the most common (9.7%). 6.2% of the patients died with an average death age of 60.8 years. 44.8% of patients received treatment with bisphosphonates and 10.4% had affected relatives. The real situation of the OI in the VR has been established, which will allow a better planning in the health actions to improve the quality of life of the affected ones and their families.

15 November 2023
Verified
Journal Article
Closed access
MPMiriam de la Natividad Palomares
Miriam de la Natividad Palomares
LBLAIA BARRACHINA-BONET
LAIA BARRACHINA-BONET
LGLaura Garcia-Villodre
Laura Garcia-Villodre
SGSandra Guardiola-Vilarroig
Sandra Guardiola-Vilarroig
Oscar ZurriagaOscar Zurriaga
Oscar Zurriaga
CCClara Cavero-Carbonell
Clara Cavero-Carbonell